Healthcare provider profile · identity verified

Robert W Hodge, MD

Family Practice · CREESTWOOD, KY · NPI 1578632006

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Lisinopril	Lisinopril	383	101
Levothyroxine Sodium	Levothyroxine Sodium	345	94
Atorvastatin Calcium	Atorvastatin Calcium	305	83
Simvastatin	Simvastatin	282	75
Amlodipine Besylate	Amlodipine Besylate	281	78
Metoprolol Succinate	Metoprolol Succinate	247	75
Alprazolam	Alprazolam	223	51
Rosuvastatin Calcium	Rosuvastatin Calcium	212	69
Pantoprazole Sodium	Pantoprazole Sodium	199	63
Omeprazole	Omeprazole	179	50
Metformin Hcl	Metformin Hcl	175	52
Tramadol Hcl	Tramadol Hcl	163	45
Zolpidem Tartrate	Zolpidem Tartrate	155	47
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	144	36
Alendronate Sodium	Alendronate Sodium	132	32
Clonidine Hcl	Clonidine Hcl	114	30
Meloxicam	Meloxicam	108	39
Tamsulosin Hcl	Tamsulosin Hcl	108	34
Escitalopram Oxalate	Escitalopram Oxalate	107	31
Furosemide	Furosemide	107	33
Eliquis	Apixaban	105	30
Gabapentin	Gabapentin	103	37
Irbesartan	Irbesartan	102	32
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	101	36
Allopurinol	Allopurinol	96	29
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	96	26
Pravastatin Sodium	Pravastatin Sodium	84	26
Diclofenac Sodium	Diclofenac Sodium	80	30
Albuterol Sulfate Hfa	Albuterol Sulfate	79	33
Losartan Potassium	Losartan Potassium	76	23
Ezetimibe	Ezetimibe	75	19
Trazodone Hcl	Trazodone Hcl	74	19
Citalopram Hbr	Citalopram Hydrobromide	70	17
Metoprolol Tartrate	Metoprolol Tartrate	70	22
Carvedilol	Carvedilol	66	16
Clopidogrel	Clopidogrel Bisulfate	66	21
Hydrochlorothiazide	Hydrochlorothiazide	64	21
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	64	18
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	57	suppressed
Celecoxib	Celecoxib	56	15
Sertraline Hcl	Sertraline Hcl	56	19
Atenolol	Atenolol	54	16
Baclofen	Baclofen	49	14
Fluticasone Propionate	Fluticasone Propionate	48	16
Montelukast Sodium	Montelukast Sodium	46	16
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	44	12
Famotidine	Famotidine	42	16
Fenofibrate	Fenofibrate	38	13
Duloxetine Hcl	Duloxetine Hcl	36	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	34	suppressed
Mirtazapine	Mirtazapine	34	suppressed
Bupropion Xl	Bupropion Hcl	32	suppressed
Glyburide	Glyburide	32	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	32	suppressed
Meclizine Hcl	Meclizine Hcl	32	11
Paroxetine Hcl	Paroxetine Hcl	32	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	31	suppressed
Potassium Chloride	Potassium Chloride	31	suppressed
Methylprednisolone	Methylprednisolone	30	29
Prednisone	Prednisone	30	25
Fluoxetine Hcl	Fluoxetine Hcl	29	suppressed
Glipizide	Glipizide	29	suppressed
Azithromycin	Azithromycin	28	26
Synthroid	Levothyroxine Sodium	28	suppressed
Nitroglycerin	Nitroglycerin	27	17
Triamcinolone Acetonide	Triamcinolone Acetonide	27	14
Spironolactone	Spironolactone	26	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	25	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	23	suppressed
Glimepiride	Glimepiride	23	suppressed
Lorazepam	Lorazepam	23	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	23	17
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	22	20
Ciprofloxacin Hcl	Ciprofloxacin Hcl	20	17
Fenofibrate	Fenofibrate Nanocrystallized	20	suppressed
Propranolol Hcl	Propranolol Hcl	20	suppressed
Hydralazine Hcl	Hydralazine Hcl	19	suppressed
Ozempic	Semaglutide	19	suppressed
Promethazine Hcl	Promethazine Hcl	19	suppressed
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	18	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	18	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	18	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	18	12
Topiramate	Topiramate	18	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	17	suppressed
Estradiol	Estradiol	17	suppressed
Farxiga	Dapagliflozin Propanediol	17	suppressed
Fluconazole	Fluconazole	17	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	17	suppressed
Memantine Hcl	Memantine Hcl	17	suppressed
Naproxen	Naproxen	17	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	17	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	17	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	16	suppressed
Benazepril Hcl	Benazepril Hcl	16	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	16	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	16	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	16	suppressed
Valsartan	Valsartan	16	suppressed
Atenolol-Chlorthalidone	Atenolol/Chlorthalidone	15	suppressed
Digoxin	Digoxin	15	suppressed
Hydrocortisone	Hydrocortisone	15	12
Januvia	Sitagliptin Phosphate	14	suppressed
Levofloxacin	Levofloxacin	14	14
Nifedipine Er	Nifedipine	14	suppressed
Ramipril	Ramipril	14	suppressed
Warfarin Sodium	Warfarin Sodium	14	suppressed
Diazepam	Diazepam	13	suppressed
Levetiracetam	Levetiracetam	13	suppressed
Tizanidine Hcl	Tizanidine Hcl	13	suppressed
Amiodarone Hcl	Amiodarone Hcl	12	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	12	suppressed
Methocarbamol	Methocarbamol	12	suppressed
Raloxifene Hcl	Raloxifene Hcl	12	suppressed
Terbinafine Hcl	Terbinafine Hcl	12	suppressed
Cefdinir	Cefdinir	11	suppressed
Ropinirole Hcl	Ropinirole Hcl	11	suppressed
Theophylline Er	Theophylline Anhydrous	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error